serogroup c neisseria meningitidis

Summary

Summary: Strains of Neisseria meningitidis responsible for most sporadic cases in teenagers and almost all outbreaks of disease in this age group. These strains are less common in infants.

Top Publications

  1. Snape M, Kelly D, Lewis S, Banner C, Kibwana L, Moore C, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ. 2008;336:1487-91 pubmed publisher
    ..To determine the persistence of bactericidal antibody titres following immunisation with serogroup C meningococcal glycoconjugate vaccine at age 6-15 years in order to examine changes in persistence of antibodies with age...
  2. Trotter C, Andrews N, Kaczmarski E, Miller E, Ramsay M. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365-7 pubmed
    ..The number of individuals in these cohorts remains low, but alternative routine immunisation schedules should be considered to ensure high levels of protection are sustained...
  3. Tsang R, Zollinger W. Serological specificities of murine hybridoma monoclonal antibodies against Neisseria meningitidis serogroups B, C, Y, and W135 and evaluation of their usefulness as serogrouping reagents by indirect whole-cell enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2005;12:152-6 pubmed
    ..The advantage of using MAbs for serogrouping of meningococci is discussed...
  4. Snape M, Kelly D, Green B, Moxon E, Borrow R, Pollard A. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J. 2005;24:128-31 pubmed
    ..A serum bactericidal titer of <1/8 correlates with susceptibility to invasive meningococcal disease. We assessed this correlate of protection in a cohort of children approximately 2 years after a single dose of vaccine...
  5. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine. 2005;23:2222-7 pubmed
    ..SBA activity as a correlate of protection for evaluating the immune response to meningococcal vaccines is described in this review...
  6. Larrauri A, Cano R, Garcia M, Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005;23:4097-100 pubmed
    ..Accordingly, there is a need for ongoing re-evaluation of VE and ascertainment of long-term vaccine protection. The findings reported would allow to decide on the advisability of revising current vaccination guidelines...
  7. Backhouse J, Gidding H, Macintyre C, McIntyre P, Gilbert G. Population-based seroprevalence of Neisseria meningitidis serogroup C capsular antibody before the introduction of conjugate vaccine, in Australia. Vaccine. 2007;25:1310-5 pubmed
    ..52 U/mL versus 0.41 U/mL; p=0.005). The ELISA appears suitable for serosurveillance but the IgG level that correlates with protection needs further investigation. Serosurveys will be repeated to monitor the impact of vaccination...
  8. Mastrantonio P, Sofia T, Neri A, Fazio C, Stefanelli P. Characterisation of invasive meningococcal isolates from Italian children and adolescents. Clin Microbiol Infect. 2007;13:100-3 pubmed
    ..5,2, which belongs to the hyper-virulent ST8/A4 cluster...
  9. Zhang T, He J, He X, Chen L, Shao Z, Sun M. The molecular characterization of serogroup C Neisseria meningitidis strains circulating in Beijing. J Microbiol. 2006;44:685-8 pubmed
    The aim of this study was to characterize the molecular features of serogroup C Neisseria meningitidis strains circulating in Beijing, China. Twenty out of 23 strains belonged to ST 4821...

More Information

Publications143 found, 100 shown here

  1. Kafetzis D, Stamboulidis K, Tzanakaki G, Kourea Kremastinou J, Skevaki C, Konstantopoulos A, et al. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians. Clin Microbiol Infect. 2007;13:550-2 pubmed
    ..This vaccination scheme has probably contributed to a dramatic decrease in the number of meningococcal C infections, which reached zero in 2004...
  2. Ceyhan M, Yildirim I, Balmer P, Riley C, Laher G, Andrews N, et al. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005. Vaccine. 2007;25:7233-7 pubmed
  3. Maiden M, Ibarz Pavón A, Urwin R, Gray S, Andrews N, Clarke S, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737-43 pubmed publisher
    ..The impact of this intervention on asymptomatic carriage of meningococci was investigated to establish whether serogroup replacement or protection by herd immunity occurred...
  4. de Voer R, Schepp R, Versteegh F, van der Klis F, Berbers G. Simultaneous detection of Haemophilus influenzae type b polysaccharide-specific antibodies and Neisseria meningitidis serogroup A, C, Y, and W-135 polysaccharide-specific antibodies in a fluorescent-bead-based multiplex immunoassay. Clin Vaccine Immunol. 2009;16:433-6 pubmed publisher
    ..96). Furthermore, no cross-reactivity between HibPS and the four meningococcal serogroups was detected. This pentaplex meningococcal Hib MIA is a useful tool to investigate serological responses toward different childhood PS vaccines...
  5. de Voer R, van der Klis F, Nooitgedagt J, Versteegh F, van Huisseling J, van Rooijen D, et al. Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis. Clin Infect Dis. 2009;49:58-64 pubmed publisher
    ..The seroprevalence of antibodies specific for polysaccharide or protein antigens from vaccine-preventable pathogens was determined in paired maternal delivery and cord blood serum samples...
  6. Sakou I, Tzanakaki G, Tsolia M, Sioumala M, Barbouni A, Kyprianou M, et al. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine. Vaccine. 2009;27:4408-11 pubmed publisher
  7. Diez Domingo J, Cantarino M, Torrentí J, Sansano M, Rosich A, Merino A, et al. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J. 2010;29:148-52 pubmed publisher
    ..A booster meningococcal C (MenC) vaccine dose is recommended after the first year of life. The objective of this study was to assess its immunogenicity and factors that modify the immunoresponse...
  8. Gray S, Trotter C, Ramsay M, Guiver M, Fox A, Borrow R, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol. 2006;55:887-96 pubmed
  9. Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194:1745-52 pubmed
    ..The meningococcal serogroup C conjugate (MCC) vaccine was introduced into the United Kingdom with licensure based on immunogenicity data not efficacy data...
  10. Booy R, Jelfs J, El Bashir H, Nissen M. Impact of meningococcal C conjugate vaccine use in Australia. Med J Aust. 2007;186:108-9 pubmed
  11. Zhang X, Shao Z, Yang E, Xu L, Xu X, Li M, et al. Molecular characterization of serogroup C Neisseria meningitidis isolated in China. J Med Microbiol. 2007;56:1224-9 pubmed
    ..In addition, the proportion of serogroup C Neisseria meningitidis isolates from sporadic cases and carriers has also increased...
  12. Prinz D, Smithson S, Westerink M. Two different methods result in the selection of peptides that induce a protective antibody response to Neisseria meningitidis serogroup C. J Immunol Methods. 2004;285:1-14 pubmed
    ..This study demonstrates that two different selection methods, production of an anti-id and biopanning using a phage display library, can be used to select functional and protective peptides of MCPS with similar moieties. ..
  13. Trotter C, Ramsay M, Kaczmarski E. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun Dis Public Health. 2002;5:220-5 pubmed
  14. Steenbergen S, Vimr E. Functional relationships of the sialyltransferases involved in expression of the polysialic acid capsules of Escherichia coli K1 and K92 and Neisseria meningitidis groups B or C. J Biol Chem. 2003;278:15349-59 pubmed
    ..The combined results provide the first evidence for residues critical to acceptor binding and elongation in polysialyltransferase...
  15. Pelton S, Gilmet G. Expanding prevention of invasive meningococcal disease. Expert Rev Vaccines. 2009;8:717-27 pubmed publisher
  16. Gaucher S, Stephanazzi J, Jarraya M. Human skin allografts as a useful adjunct in the treatment of purpura fulminans. J Wound Care. 2010;19:355-8 pubmed
    ..Recourse to human skin allografts must be considered a pertinent therapeutic option in patients with purpura fulminans. ..
  17. de Souza A, de Oliveira A, Romano C, Sztajnbok J, Duarte A, Seguro A. Interleukin-6 activation in ischemic stroke caused by Neisseria meningitidis serogroup C. Int J Cardiol. 2008;127:e160-3 pubmed
    ..Concentrations of interleukin-6 were notably elevated in the cerebrospinal fluid. We also discuss some clinical and pathophysiological features of cerebrovascular injury in meningococcal disease. ..
  18. Peng J, Yang L, Yang F, Yang J, Yan Y, Nie H, et al. Characterization of ST-4821 complex, a unique Neisseria meningitidis clone. Genomics. 2008;91:78-87 pubmed
    ..Genome comparison between the newly emerged hyperinvasive isolates belonging to different serogroups will further our understanding of their respective pathogenetic mechanisms. ..
  19. Kremastinou J, Tzanakaki G, Levidiotou S, Markou F, Themeli E, Voyiatzi A, et al. Carriage of Neisseria meningitidis and Neisseria lactamica in northern Greece. FEMS Immunol Med Microbiol. 2003;39:23-9 pubmed
    ..5,2 strain responsible for increased disease activity in Greece in either the immigrant or local populations...
  20. Schmitt H, Maechler G, Habermehl P, Knuf M, Saenger R, Begg N, et al. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin Vaccine Immunol. 2007;14:426-34 pubmed
    ..A Hib-MenC-TT conjugate vaccine provides vaccination against two major pathogens in a single injection and is a suitable candidate for use in primary or booster vaccination schedules. ..
  21. Baruque Ramos J, Hiss H, Converti A, Gonçalves V, Raw I. Accumulation of organic acids in cultivations of Neisseria meningitidis C. J Ind Microbiol Biotechnol. 2006;33:869-77 pubmed
    ..A survey of possible metabolic causes of this behavior suggested that N. meningitidis may employ different metabolic pathways for the carbon source uptake depending on the cultivation conditions. ..
  22. Boscacci R, Leib S. [Invasive meningococcal infections: two cases that demonstrate the broad spectrum in clinical manifestation and outcome]. Praxis (Bern 1994). 2006;95:1675-8 pubmed
    ..Thus meningitis may be seen as a consequence of lower pathogenicity and/or more efficient host control of the meningococci compared to sepsis. ..
  23. Davison K, Ramsay M, Crowcroft N, Lieftucht A, Kaczmarski E, Trotter C, et al. Estimating the burden of serogroup C meningococcal disease in England and Wales. Commun Dis Public Health. 2002;5:213-9 pubmed
    ..The vaccination programme has since been justified by the dramatic reduction in serogroup C meningococcal cases. ..
  24. Amir Kroll H, Riveron L, Sarmiento M, Sierra G, Acosta A, Cohen I. A conjugate vaccine composed of a heat shock protein 60 T-cell epitope peptide (p458) and Neisseria meningitidis type B capsular polysaccharide. Vaccine. 2006;24:6555-63 pubmed
    ..The vaccine was also immunogenic when injected in PBS. Thus, the p458 carrier peptide can induce T-cell help for the switch to IgG Ab to the MnB antigen...
  25. Pollard A, Ochnio J, Ho M, Callaghan M, Bigham M, Dobsong S. Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America. Emerg Infect Dis. 2004;10:1812-5 pubmed
  26. Esler D, Lewis P. Meningococcal septicaemia and a case of clinically mild illness. Commun Dis Intell Q Rep. 2007;31:232-3 pubmed
  27. Stefanelli P, Fazio C, Sofia T, Neri A, Mastrantonio P. Serogroup C meningococci in Italy in the era of conjugate menC vaccination. BMC Infect Dis. 2009;9:135 pubmed publisher
  28. Harrison L, Mohan N, Kirkpatrick P. Meningococcal group A, C, Y and W-135 conjugate vaccine. Nat Rev Drug Discov. 2010;9:429-30 pubmed publisher
  29. Ramsay M, Andrews N, Trotter C, Kaczmarski E, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326:365-6 pubmed
  30. Caniça M, Dias R, Nunes B, Carvalho L, Ferreira E. Invasive culture-confirmed Neisseria meningitidis in Portugal: evaluation of serogroups in relation to different variables and antimicrobial susceptibility (2000-2001). J Med Microbiol. 2004;53:921-5 pubmed
    ..001). This work reinforces the importance for public health of monitoring the serogroup and antimicrobial susceptibility of isolates from patients with invasive meningococcal disease...
  31. Tsolia M, Theodoridou M, Tzanakaki G, Vlachou V, Mostrou G, Stripeli F, et al. Invasive meningococcal disease in children in Greece: comparison of serogroup A disease with disease caused by other serogroups. Eur J Clin Microbiol Infect Dis. 2006;25:449-56 pubmed
    ..Serogroup B is predominant in our area, and the introduction of an effective vaccine against it is a priority. Serogroup A has emerged as the second most common serogroup, but the illness associated with it is milder...
  32. Bischoff A. [Meningococcal infections. Every case a preventable tragedy]. MMW Fortschr Med. 2008;150:17 pubmed
  33. Lansley M, Bedford H. Reflections on the meningococcal group C infection immunisation campaign: views from the sharp end. Vaccine. 2003;21:2877-81 pubmed
    ..Following the campaign, a survey of Immunisation Co-ordinators in England was conducted to identify strengths and weaknesses of the campaign. This paper summarises the main findings. ..
  34. Hérault T, Stoller J, Liard Zmuda A, Mallet E. [Peritonitis as a first manifestation of Neisseria type C meningitis]. Arch Pediatr. 2006;13:456-8 pubmed
    ..However Neisseria meningitidis type C was detected by direct peritoneal fluid examination and by 24(th) hour blood culture. Peritoneal and the CSF fluid culture were negative, but DNA analysis from peritoneal fluid was positive. ..
  35. Basler M, Linhartova I, Halada P, Novotna J, Bezousková S, Osicka R, et al. The iron-regulated transcriptome and proteome of Neisseria meningitidis serogroup C. Proteomics. 2006;6:6194-206 pubmed
    ..Comparisons with published transcriptomic data for N. meningitidis serogroup B, moreover, indicate that expression of up to 20% of all meningococcal genes can be subject to regulation in function of iron availability. ..
  36. Fusco P, Farley E, Huang C, Moore S, Michon F. Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation. Clin Vaccine Immunol. 2007;14:577-84 pubmed
  37. Baudner B, Giuliani M, Verhoef J, Rappuoli R, Junginger H, Giudice G. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine. 2003;21:3837-44 pubmed
    ..These results demonstrate that the concomitant use of chitosan microparticles and the LTK63 mutant significantly enhances the immunogenicity and the protective efficacy of vaccines given intranasally. ..
  38. Spoulou V, Moschou C, Tzanakaki G, Theodoridou M. Conjugate vaccine-induced immunological priming is not protective against acute meningococcal C infection. Vaccine. 2007;25:7012-3 pubmed
  39. Harrison L, Shutt K, Schmink S, Marsh J, Harcourt B, Wang X, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005. J Infect Dis. 2010;201:1208-24 pubmed publisher
    ..The high prevalence of capsular switching requires surveillance to detect changes in the meningococcal population structure that may affect the effectiveness of meningococcal vaccines. ..
  40. Levy Bruhl D, Perrocheau A, Mora M, Taha M, Dromell Chabrier S, Beytout J, et al. Vaccination campaign following an increase in incidence of serogroup C meningococcal diseases in the department of Puy-de-Dôme (France). Euro Surveill. 2002;7:74-6 pubmed
    ..More than half of the 1390 immediate side effects were headache and dizziness. As of mid-March, no further case of meningococcal disease has been notified since 6 January. ..
  41. Shao Z, Li W, Ren J, Liang X, Xu L, Diao B, et al. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China. Lancet. 2006;367:419-23 pubmed
    ..The emergence of this sequence type has epidemiological importance that should be monitored for future spread in China and the rest of the world. ..
  42. Zarantonelli M, Szatanik M, Giorgini D, Hong E, Huerre M, Guillou F, et al. Transgenic mice expressing human transferrin as a model for meningococcal infection. Infect Immun. 2007;75:5609-14 pubmed
    ..Thus, transgenic mice expressing human transferrin may represent an important advance as a new mouse model for in vivo studies of meningococcal virulence and immunogenicity factors. ..
  43. Buijze G, Snoep A, Brevoord J. Serogroup C meningococcal osteomyelitis: a case report and review of the literature. Pediatr Infect Dis J. 2009;28:929-30 pubmed
    ..Meningococcal osteomyelitis is exceptionally rare and to our knowledge, serogroup C meningococci have not been previously reported as a cause. ..
  44. Gomez Lus M, Gimenez M, Vazquez J, Aguilar L, Anta L, Berron S, et al. Opsonophagocytosis versus complement bactericidal killing as effectors following Neisseria meningitidis group C vaccination. Infection. 2003;31:51-4 pubmed
    ..PMN did not increase post-vaccination bacterial killing, suggesting that antibody complement-mediated killing, and not opsonophagocytosis, is the main immune effector of the vaccine protection against N. meningitidis. ..
  45. de Lemos A, Yara T, Gorla M, de Paiva M, de Souza A, Gonçalves M, et al. Clonal distribution of invasive Neisseria meningitidis serogroup C strains circulating from 1976 to 2005 in greater Sao Paulo, Brazil. J Clin Microbiol. 2007;45:1266-73 pubmed
    ..The antigenic replacements we observed likely represent a mechanism to sustain meningococcal disease in the population as immunity to circulating strains accumulated. ..
  46. Trotter C, Findlow J, Balmer P, Holland A, Barchha R, Hamer N, et al. Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin Vaccine Immunol. 2007;14:863-8 pubmed
    ..With the exception of children aged 3 to 11 months, there was no clear relationship between disease incidence and seroprevalence. ..
  47. Pace D, Pollard A, Messonier N. Quadrivalent meningococcal conjugate vaccines. Vaccine. 2009;27 Suppl 2:B30-41 pubmed publisher
    ..This vaccine and others in development offer the potential to broaden population protection against meningococcal disease...
  48. Davison K, Crowcroft N, Ramsay M, Begg N, Kaczmarski E, Stuart J, et al. Enhanced surveillance scheme for suspected meningococcal disease in five regional health authorities in England: 1998. Commun Dis Public Health. 2002;5:205-12 pubmed
    ..These data were used to inform the national meningococcal serogroup C conjugate vaccination programme in England and Wales. In 1999 ESMD was extended to all regions of England, Wales and Northern Ireland. ..
  49. Lal G, Balmer P, Joseph H, Dawson M, Borrow R. Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin Diagn Lab Immunol. 2004;11:272-9 pubmed
    ..The tetraplex assay has the potential to be an important addition to the serologic evaluation of meningococcal capsular polysaccharide conjugate vaccines...
  50. van den Berg J, Westerbeek E, Berbers G, van Gageldonk P, van der Klis F, van Elburg R. Transplacental transport of IgG antibodies specific for pertussis, diphtheria, tetanus, haemophilus influenzae type b, and Neisseria meningitidis serogroup C is lower in preterm compared with term infants. Pediatr Infect Dis J. 2010;29:801-5 pubmed
  51. de Greeff S, de Melker H, Spanjaard L, van den Hof S, Dankert J. [The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients]. Ned Tijdschr Geneeskd. 2003;147:1132-5 pubmed
    ..There was also a decrease in the unvaccinated age groups. The vaccination campaign led almost immediately to a sharp decrease in the number of patients with meningococcal serogroup-C disease. ..
  52. de Souza A, Salgado M, Alkmin M, Sztajnbok J, Seguro A. Purulent pericarditis caused by Neisseria meningitidis serogroup C and confirmed through polymerase chain reaction. Scand J Infect Dis. 2006;38:143-5 pubmed
    ..Polymerase chain reaction was used to identify Neisseria meningitidis serogroup C as the causative agent in the pericardial fluid. ..
  53. Rezaei N, Aghamohammadi A, Siadat S, Nejati M, Ahmadi H, Moin M, et al. Serum bactericidal antibody response to serogroup C polysaccharide meningococcal vaccination in children with primary antibody deficiencies. Vaccine. 2007;25:5308-14 pubmed
    ..This supports the use of polysaccharide-containing vaccines in these patients. ..
  54. Pugh R, Heseltine A. A case of meningococcal disease in a schoolgirl previously given meningococcal C vaccine. Commun Dis Public Health. 2002;5:74 pubmed
  55. Ruggeberg J, Pollard A. Meningococcal vaccines. Paediatr Drugs. 2004;6:251-66 pubmed
  56. Ehrhard I, Arndt U. [Public health management in invasive meningococcal diseases]. Gesundheitswesen. 2004;66:790-5 pubmed
    ..In the workshop, Professor Ulrich Vogel and Dr. Ingrid Ehrhard presented the epidemiological situation in Germany and the recommended prophylaxis regimen against meningococci. ..
  57. Cavrini F, Liguori G, Andreoli A, Sambri V. Multiple nucleotide substitutions in the Neisseria meningitidis serogroup C ctrA gene cause false-negative detection by real-time PCR. J Clin Microbiol. 2010;48:3016-8 pubmed publisher
    ..The nucleotide substitutions did not alter the corresponding protein sequences, but they impeded the detection of these meningococcal isolates by real-time PCR. ..
  58. De Wals P, Nguyen V, Erickson L, Guay M, Drapeau J, St Laurent J. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease. Vaccine. 2004;22:1233-40 pubmed
    ..If vaccine-induced immunity is waning rapidly, mass immunization or routine vaccination with booster dose(s) would be the best control options. ..
  59. Rodriguez C, Rodriguez Morales A, Garcia A, Pastran B, Rios A, Calvo A, et al. Quinolone and azithromycin-resistant Neisseria meningitidis serogroup C causing urethritis in a heterosexual man. Int J STD AIDS. 2005;16:649-50 pubmed
  60. Yu J, Borkowski A, Danzig L, Reiter S, Kavan P, Mazer B. Immune response to conjugated meningococcal C vaccine in pediatric oncology patients. Pediatr Blood Cancer. 2007;49:918-23 pubmed
    ..001). Meningococcal C-conjugate vaccine produced variable responses in children with common cancers. Proximity to chemotherapy and total B cell number may help predict likelihood of response. ..
  61. Zhu P, Tsai C, Frasch C. Immunologic and genetic characterization of lipooligosaccharide variants in a Neisseria meningitidis serogroup C strain. FEMS Immunol Med Microbiol. 2002;34:193-200 pubmed
    ..These findings suggest that besides phase variation, homologous recombination can contribute to the genetic diversity of the lgt locus and to the generation of LOS variation in N. meningitidis. ..
  62. Prinz D, Smithson S, Kieber Emmons T, Westerink M. Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide. Immunology. 2003;110:242-9 pubmed
    ..The DNA construct induced a significant anti-polysaccharide antibody response that was bactericidal. Mice immunized with the DNA construct were subsequently protected against challenge with a lethal dose of N. meningitidis serogroup C. ..
  63. Max A, Duchateau F, Compagnon F, Rosenstingl S, Fillion A, Bonneton B, et al. [Serogroup C meningococcemia presenting as pericarditis in a 55-year-old woman without medical history]. Ann Fr Anesth Reanim. 2007;26:452-4 pubmed
    ..We report the clinical and paraclinical signs that lead us to the diagnosis in a 55-year-old woman with favourable evolution. Previously described predisposing factors were no found. ..
  64. Falcao M, Andrade S, Ceccon M, Costa Vaz F. Neonatal sepsis and meningitis caused by Neisseria meningitidis: a case report. Rev Inst Med Trop Sao Paulo. 2007;49:191-4 pubmed
    ..This report emphasizes the need to prevent the premature exposure of newborn infants to pathological agents, especially if they presented birth injuries and/or are preterm, due to their lack of immunological capacity. ..
  65. Pace D. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy. Expert Rev Vaccines. 2009;8:529-42 pubmed publisher
    ..This article discusses this novel quadrivalent vaccine formulation and its potential to control invasive disease caused by N. meningitidis serogroups A, C, Y and W-135...
  66. Gidney M, Plested J, Lacelle S, Coull P, Wright J, Makepeace K, et al. Development, characterization, and functional activity of a panel of specific monoclonal antibodies to inner core lipopolysaccharide epitopes in Neisseria meningitidis. Infect Immun. 2004;72:559-69 pubmed
    ..meningitidis strains. These findings are provocative with respect to the requirements for protective activity of antibodies and the development of inner core LPS vaccines against invasive meningococcal disease. ..
  67. Pérez A, Dickinson F, Banderas F, Serrano T, Llanes R, Guzmán D, et al. Safety and preliminary immunogenicity of MenC/P64k, a meningococcal serogroup C conjugate vaccine with a new recombinant carrier. FEMS Immunol Med Microbiol. 2006;46:386-92 pubmed
    ..05). The MenC/P64k vaccine was found to have a good safety profile, to be well tolerated and immunogenic. ..
  68. Fessler B. ["Typical" symptoms are frequently absent. Every 10th meningococcal C infection is fatal]. MMW Fortschr Med. 2006;148:19 pubmed
  69. Pace D, Snape M, Westcar S, Hamaluba M, Yu L, Begg N, et al. A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants. Pediatr Infect Dis J. 2007;26:1057-9 pubmed
    ..SBA MenC titers > or =1:8 and anti-PRP concentrations > or =0.15 microg/mL were measured in 99.2% and 100%, respectively, of the infants receiving Hib-MenC-TT...
  70. Bettinger J, Scheifele D, Le Saux N, Halperin S, Vaudry W, Tsang R. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J. 2009;28:220-4 pubmed publisher
    ..A substantial decrease in group C incidence occurred in provinces with early MenC immunization programs. Serogroup C incidence remained stable in provinces without MenC programs. We found no evidence of serogroup replacement. ..
  71. Moe G, Bhandari T, Flitter B. Vaccines containing de-N-acetyl sialic acid elicit antibodies protective against neisseria meningitidis groups B and C. J Immunol. 2009;182:6610-7 pubmed publisher
    ..meningitidis group C strain with human complement. Thus, de-N-acetyl PSA Ags are immunogenic and elicit Abs that can be protective against MenB and N. meningitidis group C strains. ..
  72. Noack R. [Meningococcus, serogroup C]. Krankenpfl J. 2005;43:16 pubmed
  73. Kugelberg E, Gollan B, Farrance C, Bratcher H, Lucidarme J, Ibarz Pavón A, et al. The influence of IS1301 in the capsule biosynthesis locus on meningococcal carriage and disease. PLoS ONE. 2010;5:e9413 pubmed publisher
    Previously we have shown that insertion of IS1301 in the sia/ctr intergenic region (IGR) of serogroup C Neisseria meningitidis (MenC) isolates from Spain confers increased resistance against complement-mediated killing...
  74. Offit P, Peter G. Meningococcal conjugate vaccine in the UK: an update. Lancet. 2004;364:309-10 pubmed
  75. De Wals P. Meningococcal C vaccines: the Canadian experience. Pediatr Infect Dis J. 2004;23:S280-4 pubmed
    Several outbreaks caused by virulent strains of serogroup C Neisseria meningitidis were observed in several Canadian provinces in the early 1990s...
  76. Guirola M, Carmenate T, Menéndez T, Alvarez A, Gonzalez S, Guillen G. Comparison of three ELISA protocols to measure antibody responses elicited against serogroup C meningococcal polysaccharide in mouse, monkey and human sera. J Microbiol Methods. 2006;65:135-43 pubmed
    ..05), while the modified protocol detected the highest difference (P<0.01). ..
  77. Henneken M, Burdin N, Thoroddsen E, Sigurdardottir S, Trannoy E, Jonsdottir I. Meningococcal serogroup C polysaccharide specific memory B cells, directly enumerated by labeled polysaccharide, are not affected by age at vaccination. Vaccine. 2010;28:2097-103 pubmed publisher
    ..The percentage of MenC-specific memory B cells out of total memory B cells correlated with total MenC-specific B-cells and with frequencies of IgA(+) plus IgG(+) MenC-specific AbSC, but not with MenC-specific Ab. ..
  78. Perrett K, Winter A, Kibwana E, Jin C, John T, Yu L, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis. 2010;50:1601-10 pubmed publisher
    ..A booster was highly effective in this cohort and could sustain population immunity against MenC disease. Trial registration. Current Controlled Trials ( http://www.controlled-trials.com ) identifier: ISRCTN72858898 . ..
  79. Salleras L, Dominguez A, Cardenosa N. Impact of mass vaccination with polysaccharide conjugate vaccine against serogroup C meningococcal disease in Spain. Vaccine. 2003;21:725-8 pubmed
    ..During 2001, the incidence rate of meningococcal C disease was still lower (0.32 per 100000 persons-year) in the regions that vaccinated in 1997 with the polysaccharide vaccine than in those that did not (0.64 per 100000 persons-year). ..
  80. Bricks L. Critical analysis of old and new vaccines against N. meningitidis serogroup C, considering the meningococcal disease epidemiology in Brazil. Rev Hosp Clin Fac Med Sao Paulo. 2003;58:231-40 pubmed
  81. Jokhdar H, Borrow R, Sultan A, Adi M, Riley C, Fuller E, et al. Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol. 2004;11:83-8 pubmed
  82. Welte R, van den Dobbelsteen G, Bos J, de Melker H, van Alphen L, Spanjaard L, et al. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine. 2004;23:470-9 pubmed
    ..These results played a major role in the decision to add meningococcal C vaccination to the routine childhood immunisation schedule at 14 months and to implement a catch-up vaccination programme in The Netherlands in 2002. ..
  83. Ploy M, Garnier F, Languepin J, Fermeaux V, Martin C, Denis F. Interest of postmortem-collected specimens in the diagnosis of fulminant meningococcal sepsis. Diagn Microbiol Infect Dis. 2005;52:65-6 pubmed
    ..We were able to identify the bacteria by culture and/or PCR on samples without having autopsy performed. Soluble antigens were also detected in serum. ..
  84. Tsang R, Law D, Henderson A, Blake M, Stoltz J. Increase in serogroup C meningococcal disease in Canada is associated with antigenic changes in the protein antigens of the ET-15 clone of Neisseria meningitidis. J Infect Dis. 2006;194:1791-2; author reply 1792-3 pubmed
  85. Agarwal S, Ferreira V, Cortes C, Pangburn M, Rice P, Ram S. An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae. J Immunol. 2010;185:507-16 pubmed publisher
    ..meningitidis or N. gonorrhoeae but play a crucial role in augmenting AP-dependent C3 deposition on the bacteria through the "conventional" mechanism of stabilizing AP C3 convertases...
  86. Granoff D, Morgan A, Welsch J. Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J. 2005;24:132-6 pubmed
    ..However, serum antibody concentrations in many vaccinated children were no longer sufficient to activate complement-mediated bacteriolysis in vitro or to confer passive protection against experimental group C disease. ..
  87. De Wals P. Immunization strategies for the control of serogroup C meningococcal disease in developed countries. Expert Rev Vaccines. 2006;5:269-75 pubmed
    ..A schedule consisting of a first dose around 1 year of age and a second dose around 12 years of age seems to be a very cost-effective option in most epidemiological scenarios. ..
  88. Chanteau S, Dartevelle S, Mahamane A, Djibo S, Boisier P, Nato F. New rapid diagnostic tests for Neisseria meningitidis serogroups A, W135, C, and Y. PLoS Med. 2006;3:e337 pubmed
    ..meningitidis serogroup determination is key. To this end, we developed and evaluated two duplex rapid diagnostic tests (RDTs) for detecting N. meningitidis polysaccharide (PS) antigens of several important serogroups...
  89. Wiese Posselt M, Hellenbrand W, Siedler A, Mayer C. Universal childhood immunisation with pneumococcal vaccine and meningococcal serogroup C vaccine introduced in Germany. Euro Surveill. 2006;11:E060907.4 pubmed
  90. Bentley S, Vernikos G, Snyder L, Churcher C, Arrowsmith C, Chillingworth T, et al. Meningococcal genetic variation mechanisms viewed through comparative analysis of serogroup C strain FAM18. PLoS Genet. 2007;3:e23 pubmed
  91. Bergfeld A, Claus H, Lorenzen N, Spielmann F, Vogel U, Muhlenhoff M. The polysialic acid-specific O-acetyltransferase OatC from Neisseria meningitidis serogroup C evolved apart from other bacterial sialate O-acetyltransferases. J Biol Chem. 2009;284:6-16 pubmed publisher
  92. Baselier M, van Keulen P, van Wijngaarden P, Alings A. Meningococcal pericarditis and tamponade. Neth J Med. 2004;62:134-6 pubmed
    ..Moreover, she suffered from a culture-proven pyogenic pericarditis that deteriorated into cardiac tamponade. Immediate pericardiocentesis was successful and eventually the patient recovered. ..